In 2015, about 292,000 breast cancer cases are expected to be diagnosed in the women in U.S. Moreover, >40,000 women are expected to die due to breast cancer in 2015. HER2 positive breast cancer is characterized by overexpression of a protein called HER2, which causes the cells to grow rapidly and form aggressive tumors. The majority of the HER2+ patients either do not respond to clinical therapy or they stop responding after the initial response. This diminished response to the therapy causes the tumor recurrence. My study aims at understanding how Notch signaling leads to enrichment of certain cells which escape the drug treatment and then lay dormant and mediate tumor recurrence in HER2+ breast cancer. The breakthrough study will identify the novel biomarkers for predicting drug resistance, and newer drug targets for eradicating the tumor, preventing drug resistance and tumor
In 2015, about 292,000 breast cancer cases are expected to be diagnosed in the women in U.S. Moreover, >40,000 women are expected to die due to breast cancer in 2015. HER2 positive breast cancer is characterized by overexpression of a protein called HER2, which causes the cells to grow rapidly and form aggressive tumors. The majority of the HER2+ patients either do not respond to clinical therapy or they stop responding after the initial response. This diminished response to the therapy causes the tumor recurrence. My study aims at understanding how Notch signaling leads to enrichment of certain cells which escape the drug treatment and then lay dormant and mediate tumor recurrence in HER2+ breast cancer. The breakthrough study will identify the novel biomarkers for predicting drug resistance, and newer drug targets for eradicating the tumor, preventing drug resistance and tumor